The rapid and widespread clinical adoption of highly effective incretin‐mimetic drugs (IMDs),
particularly semaglutide and tirzepatide, for the treatment of obesity has outpaced the …

Today, type 2 diabetes mellitus (T2DM) and skeletal muscle atrophy (SMA) have become
increasingly common occurrences. Whether the onset of T2DM increases the risk of SMA or …

Background Oral semaglutide is the first glucagon-like peptide-1 receptor agonist (GLP-
1RA) designed for oral administration; it offers a promising opportunity to facilitate an early …

Abstract Purpose of Review Sarcopenic obesity (SO), defined as the coexistence of excess
fat mass and reduced skeletal muscle mass and strength, has emerged as an important …

Many countries are facing the advent of super-aging societies, where sarcopenia and frailty
will become pertinent problems. The prevalence of comorbidities is a major problem in …

Type 2 diabetes mellitus (T2DM) and sarcopenia (low skeletal muscle mass and function)
share a bidirectional relationship. The prevalence of these diseases increases with age and …

Aims Type 1 diabetes mellitus (T1DM) has been linked to the occurrence of skeletal muscle
atrophy. Insulin monotherapy may lead to excessive blood glucose fluctuations. N …

Background Sarcopenia, a condition characterized by diminished skeletal muscle mass,
strength, and function, accompanied by inflammation and oxidative stress, remains an area …

Excess adiposity is at the root of type 2 diabetes (T2D). Glucagon‐like peptide‐1 receptor
agonists (GLP‐1RAs) have emerged as first‐line treatments for T2D based on significant …

Background A newly developed technique, the Triglyceride-glucose (TyG) index, supplies a
more straightforward method to identify IR than the HOMA-IR (Homeostasis Model …